# AdaptImmune Therapeutics (ADAP)

Adaptimmune Therapeutics Adaptimmune Therapeutics plc ( ADAP ) announced that the U.S. FDA has accelerated the approval of TECELRA® for the treatment of adults with unresectable or metastatic synovial...

Prohost Biotech

Nov 15, 2024

Adaptimmune Therapeutics: A First Approved Treatment of Unresectable or Metastatic Synovial Sarcoma

Sonoma Pharmaceuticals and MicroSafe Group, Dubai Sonoma Pharmaceuticals ( SNOA ) develops stabilized hypochlorous acid (HOCl) products for a wide range of applications including: wound care, eye care...

Prohost Biotech

Aug 2, 2024

Why Sonoma Pharmaceuticals and Adaptimmune Stock Prices Skyrocketed

The Week in Review #23 ASCO 2018 - Small publicly-traded oncology biotech firms, large oncology biotech firms, and giant biopharmaceutical firms, in addition to some private biot...

Prohost Biotech

May 29, 2020

Good News, Bad News & Comebacks. See Also: ASCO Results

Prohost Biotech

Jun 19, 2018

8

Bellicum Pharmaceuticals (BLCM): The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in the U.S. The decision follows consultation with the FDA and agreement...

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

Prohost Biotech

Apr 12, 2018

4m

8

AT ASCO CAR-T Was Created to Stay BlueBird Bio CAR-T Results Bluebird Bio (BLUE) presentation was well received at ASCO after the firm stated results demonstrating that all the 15 evaluable patients i...

Bluebird Flies Sky-High with Its CAR-T Wings

Making Sure that CAR-T Therapy for Cancer Succeeds Academic Researchers Identify a New Process to Raise Natural Armies of Cancer-Targeting T Lymphocytes Outside the Body Unleashing More Power to the I...

Prohost Biotech

Jun 7, 2017

Academic Researchers Improve on CAR-T Immunotherapy. Guess Who the Beneficiaries Are?

The U.S. Food and Drug Administration (FDA) has removed the partial clinical hold it put on Adaptiimmune’s (ADAP) planned study of its NY ‑ ESO SPEAR ™ (Specific Peptide Enhanced Affinity Receptor) T-...

Prohost Biotech

Feb 23, 2017

Adaptimmune: The FDA Removed the Temporary Ban on the Trial with NY-ESOS PEAR T-Cell Therapy for Mixoid Round Cell Liposarcoma

Prohost Biotech

Nov 14, 2016

5

Immunotherapy Engineered T-Cell Therapy Is Here to Stay Articles aimed at undermining the value of the firms’ chimeric antigen receptor T (CAR T) cells as immunotherapy for cancer are less and less co...

Biotech Firms with Approaches Born To Stay and Succeed

Prohost Biotech

Aug 10, 2016

4m

6

EMA’s created Priority Medicines (PRIME) regulatory initiative for products which the European agency rules they are of unmet needs. PRIME makes them eligible for support, possible regulatory applicat...

Adaptimmune EMA Privileges. Different Fate for Plummeting Stocks

Le Compa G non Part 2 Wednesday June 22, 2016 From the American Society of Clinical Oncology (ASCO) Checkpoint inhibitors the CAR T Approach Adoptive cell therapy Oncolytic virus ther...

Prohost Biotech

Aug 1, 2016

Le CompaGnon Part 2

Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR Immunotherapy Approaches In this issue we continue our journey inside the territory of cancer...

Prohost Biotech

Jun 23, 2016

Prohost Letter #393

The Market is Surely Ignoring the Historical Summit Biotech achievements are standing on Right Now The latest biotech sector’s breakthroughs we presented was the novel powerful gene editing tec...

Prohost Biotech

Mar 4, 2016

Revolutionary Approaches Towards Managing Chronic and Deadly Diseases

Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY 4. CANCER IMMUNOTHERAPY 1. GENE EDITING Exon Skipping: Biomarin (BMRN); Sarepta (SRPT); These firms...

Prohost Biotech

Jan 22, 2016

Prohost Letter #388

In our yesterday’s article asking about how the FDA advisory committee has to vote regarding Biomarin product Kyndrisa ( drisapersen) for Duchenne muscular dystrophy. We got the answer yesterday durin...

Prohost Biotech

Dec 2, 2015

Biomarin: Yesterday, FDA Committee Meeting. Adaptimmune: CAR T Approach for Solid Tumors

Prohost Letter #383 The Market - Recent tails about the market and the biotech sector are true thrillers. By true we mean no-fiction. The accounts lack common sense. Professionals' interpretations of...

Prohost Biotech

Nov 25, 2015

Prohost Letter #383

Prohost Biotech

Sep 25, 2015

8

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some called it the “New Golden Boy”. During the IPO, investors who knew about this firm and were waiting for that day...

NantKwest Inc: A Novel Breathtaking Immunotherapy for Cancer?

ADAPTIMMUNE (ADAP) Data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published...

Prohost Biotech

Aug 3, 2015

Adaptimmune Data From Phase I/II Trial Demonstrate Safety and Efficacy

GILEAD SCIENCES Negative articles based on short-term technical moves areposted on the Internet aimed at rushing investors and shareholders to instigate a selloff in Gilead’s (GILD) stock. Shareholder...

Prohost Biotech

Jul 21, 2015

Technical Views on Some Prohost Picks. See Also Important News from Two Other Biotechs

Today is another day. Everyday is another day. Recently, however, at least for the sector we have been observing and following up on for over a quarter of a century, every hour is different than the h...

Prohost Biotech

Jul 2, 2015

Why Is the Biotech Index Smiling Again?

Prohost Biotech

Jun 30, 2015